Why is Beta Drugs Ltd falling/rising?

As of 14-Jul, Beta Drugs Ltd is experiencing a decline in its stock price, currently at 1,739.95, reflecting a decrease of 20.85 points or 1.18%. The stock has underperformed its sector by 2.08% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has fallen by 3.63%, while it has seen a more significant decline of 8.83% year-to-date. Despite a strong performance over the past year with a gain of 52.91%, the recent trends indicate a downturn, with rising investor participation noted through a 44.23% increase in delivery volume on July 11. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement.
In the broader market context, Beta Drugs Ltd's short-term performance has been weaker compared to the benchmark, with a 1-week decline of 3.63% against the Sensex's drop of 1.49%. While the stock has outperformed the benchmark over longer periods, such as the 1-year and 3-year returns, the recent short-term trends suggest a divergence from the overall market performance. The stock's liquidity remains adequate for trading, but the consistent underperformance relative to both its sector and the benchmark may be contributing to the downward pressure on its price.